News & Blog
March 3, 2022
The development of direct-acting antivirals transformed hepatitis C virus (HCV) therapy, allowing patients to experience fewer side effects and non-specialist providers to prescribe HCV treatment with more ease. Despite these advances, existing social and structural barriers, such as stigma and accessibility of medical care, restrict access to effective HCV treatment for people who use drugs who are co-infected with HIV and HCV.
This article is cross-posted at the University of Pennsylvania Leonard Davis Institute. Penn aluma and former Louisiana Secretary of Health Rebekah Gee detailed some of the strategies her team used to get a Medications for Opioid Use Disorder law passed in one of the country’s most conservative states. If you want to reform state laws […]
In November 2020, Oregonians voted to pass Measure 110, a ballot initiative that decriminalizes the possession of small amounts of all drugs and increases access to low-barrier substance use disorder treatment and harm reduction services. Led by the Drug Policy Alliance, the ballot measure is a historic step forward to address drug-related arrests that disproportionally […]
January 20, 2022
The evidence suggests that low-threshold approaches can increase access to treatment, with outcomes comparable to high-barrier, standard care.
As we continue to expand efforts to combat the overdose crisis, targeting our quality improvement efforts to emergency deparments with the highest opioid use disorder (OUD) visit rates could potentially benefit more than half of all patients utilizing emergency care for OUD nationwide.
During the next three years, Schackman and Martin will bring simulation modelers and policymakers together to further the science of simulation modeling by addressing issues of model design, data availability, integrity, and translation.